Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials
Article in BMJ Open (November 2020)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review
Article in Breast Cancer Research and Treatment (April 2019)
Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials
Article in Cancer Treatment Reviews (February 2019)